Telix Pharmaceuticals Ltd has released a press release.
1st Patient Dosed in ProstACT Global Randomized Tx Expansion
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
- ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
- OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
- Telix to Participate in UBS and Jefferies Global Healthcare Conferences
- Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
Later from Telix Pharmaceuticals
- Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
- ProstACT Global Study Status
- Precision Medicine Portfolio Update
- Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals